JPRN-UMIN000000898Completed未知
A comparison of lamivudine plus adefovir and entecavir for chronic hepatitis B patients whose HBV DNA levels are below the level of detection by PCR - LAM plus ADV vs ETV for HBV patients treated with LAM, randomized trial
niversity of Tokyo Department of Gastroenterology, Faculty of Medicine0 sites200 target enrollmentStarted: November 17, 2007Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The exclusion criteria are as follows: a previous history of a severe drug hypersensitivity against nucleoside analogues, malignancy within 5 years, severe renal disease (BUN more than 40 mg/dl or creatinine more than 2.0 mg/dl) the presence of other forms of liver disease such as auto immune hepatitis, coinfection with hepatitis C, history of liver transplantation, participation in another clinical trial, receiving prohibition medication for combination, and doctors' stop not to register to the study.
Investigators
Similar Trials
Completed
Not Applicable
A comparison of lamivudine plus adefovir and entecavir for chronic hepatitis B patients who had not previously received a nucleoside analogue: A randomized trialChronic hepatitis BJPRN-UMIN000000884niversity of Tokyo Department of Gastroenterology, Faculty of Medicine200
Completed
Not Applicable
Efficacy of lamivudine plus adefovir therapy or adefovir add on therapy for entecavir-resistant hepatitis B patientsCertain infectious and parasitic diseasesKCT0000085Ajou University37
Active, not recruiting
Not Applicable
A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs CombinationEntecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: TheDEFINE StudyRevised Protocol 02, incorporating protocol amendment 02 (Version 2.0, date 23-Jan-2007), protocol amendment 03 (Version 4.0, date 07-Nov-2007) and Administrative Letter 01. - The DEFINE StudyEUCTR2006-000422-31-GRBristol-Myers Squibb International Corporation462
Active, not recruiting
Not Applicable
Comparative Study of Entecavir vs Adefovir vs the Combination in Lamivudine- Refractory Chronic Hepatitis B Subjects The DEFINE Study Revised Protocol 01 - The DEFINE StudyEUCTR2006-000422-31-ITBristol-Myers Squibb International Corporation462
Unknown
Phase 3
Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis BChronic Hepatitis BNCT01270165Yonsei University110